ClinicalTrials.gg
Active, not recruitingNCT06332534U-EMPOWERUpdated Oct 16, 2026

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of Upadacitinib in Crohn's Disease, sponsored by AbbVie. Active, not recruiting at 85 sites in 18 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
18th of 27
111 · median 220
Started
2024
with 5 others
Phase 3
16 of 55
1 open now
Primary completion
2031-01
later than 11 of 13 live
Registered
48th of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 18th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2024, is one of 16 in phase 3, reaches primary completion later than 11 of the 13 other live ones, and was the 48th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.

Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given (UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide.

Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
  • Upadacitinib
  • RINVOQ
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight at Screening and Baseline must be >= 10 kg
  • Moderate to severe Crohn's Disease (CD) defined as Pediatric Crohn's Disease Activity Index (PCDAI) > 30 and endoscopic evidence of mucosal inflammation as documented by a centrally read SES-CD of >= 6 (or SES-CD of >=4 for isolated ileal disease) excluding the presence of narrowing component.
  • Documented diagnosis of CD prior to Baseline, confirmed by colonoscopy during the screening period, with exclusion of current infection, colonic dysplasia and/or . Appropriate documentation of results consistent with the diagnosis of CD, in the assessment of the investigator, must be available
  • Demonstrated an inadequate response, loss of response, or intolerance to , immunomodulators (IMMs), and/or biologic therapy or in whom use of those therapies is medically . For participants in the US and South Korea, participants must have demonstrated an inadequate response, loss of response, or intolerance to one or more anti-TNFs (tumor necrosis factor).

Exclusion criteria

Exclusion Criteria:

  • History of:

    • A diagnosis of CD prior to 2 years of age.
    • Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • More than 2 missing segments of the following 5 intestinal segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Ostomy or ileoanal pouch;
      • Surgical bowel resection within the past 3 months prior to Baseline, or a history of more than 3 bowel resections.
  • Japan participants only: positive result of beta-D-glucan or two consecutive indeterminate results of beta-D-glucan during the Screening period (screening for Pneumocystis jiroveci infection)
  • History of any of the following:

    • Current diagnosis of ulcerative colitis (UC), indeterminate colitis, or monogenic inflammatory bowel disease (IBD);
    • Fulminant colitis or toxic megacolon;
    • Gastrointestinal (GI) perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment including history of volvulus and/or intussusception (telescoping of bowels);
  • Current diagnosis of any primary immune deficiency
  • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Period 1: Open Label Induction Phase (Dose A)

    All participants in the open label induction phase of Period 1 will receive upadacitinib Dose A for 12 weeks based on body weight.

    Drug: Upadacitinib

  • Experimental
    Period 1: Double-Blind Maintenance Phase (Dose B)

    Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive Dose B or C for 52 weeks (oral solution dose will be based on body weight)

    Drug: Upadacitinib

  • Experimental
    Period 1: Double-Blind Maintenance Phase (Dose C)

    Clinical responders per PCDAI at the end of open label induction phase of Period 1 will be randomly assigned to receive either upadacitinib Dose C or B for 52 weeks (oral solution dose will be based on body weight)

    Drug: Upadacitinib

  • Experimental
    Period 2: Open Label Long-Term Extension Phase Cohort 1

    Participants receiving double-blind maintenance therapy with upadacitinib Dose B or upadacitinib Dose C daily in Period 1 who complete the Week 64 visit will receive upadacitinib Dose B daily for up to 156 weeks.

    Drug: Upadacitinib

  • Experimental
    Period 2: Open Label Long-Term Extension Phase Cohort 2

    Participants who were receiving rescue therapy with open-label upadacitinib Dose C during maintenance phase in Period 1 and completed the Week 64 visit will continue to receive upadacitinib Dose C daily for up to 156 weeks.

    Drug: Upadacitinib

  • Experimental
    Period 2: Open Label Long-Term Extension Phase Cohort 3

    Participants who did not achieve clinical response per PCDAI at Week 12 of Period 1 will receive an extended treatment with open-label upadacitinib Dose C daily for an additional 12 weeks. If they are responders after 12 weeks extended treatment, they will continue, otherwise they may be discontinued at the discretion of the investigator

    Drug: Upadacitinib

Interventions

  • Oral Solution/ Extended-Release Tablets

    Also known as: RINVOQ

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64

    PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

    Time frame: At Week 64

  2. Achievement of endoscopic response at Week 64 in participants who achieved clinical response per PCDAI at Week 12.

    Endoscopic response is defined as \> 50% reduction in Simple Endoscopic Score for Crohn's Disease (SES-CD) score from Baseline (or for participants with a Baseline SES-CD of 4, at least a 2-point reduction from Baseline), as scored by a central reader.

    Time frame: At Week 64

  3. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

    Time frame: Through Week 156

Secondary outcomes

  1. Achievement of clinical remission per PCDAI

    Clinical remission per PCDAI is defined as PCDAI ≤ 10.

    Time frame: Week 12

  2. Achievement of endoscopic response

    Endoscopic response is defined as \> 50% reduction in SES-CD score from Baseline (or for participants with a Baseline SES-CD of 4, at least a 2-point reduction from Baseline), as scored by a central reader.

    Time frame: Week 12

  3. Achievement of endoscopic remission

    Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no subscore \> 1, as scored by a central reader

    Time frame: Week 12

  4. Achievement of clinical response per PCDAI

    Clinical response is defined as reduction in PCDAI of ≥ 15 points from Baseline

    Time frame: Week 12

  5. Achievement of clinical response per PCDAI at Week 64 in participants who achieved clinical response per PCDAI at Week 12

    Time frame: Week 64

  6. Achievement of endoscopic remission at Week 64 in participants who achieved clinical response per PCDAI at Week 12

    Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no subscore \> 1, as scored by a central reader

    Time frame: Week 64

  7. Achievement of corticosteroid (CS)-free clinical remission per PCDAI at Week 64 in participants who achieved clinical response per PCDAI at Week 12

    CS-free clinical remission per PCDAI: clinical remission per PCDAI and not receiving corticosteroids at Week 12 (for Period 1 induction endpoint\[s\]); or for at least 90 days prior to the study visit at which endpoint is assessed (for Period 1 maintenance endpoint\[s\] and Period 2 endpoint\[s\]).

    Time frame: Week 64

07

Study locations

85 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2031, 77 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 77 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2027 → Jan 2031 and completion Dec 2034 → Jan 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Mar 27, 2024
StartActual
Aug 8, 2024
Primary completionEst.
Jan 2031was Jun 2027
CompletionEst.
Jan 2031was Dec 2034
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 16, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (2 Brazil, 1 France, 1 Greece, 1 Italy, 1 South Korea)
  • Hospital Pequeno Principe /ID# 262600 · Curitiba, Brazil
  • Santo Antonio Children's Hospital /ID# 262601 · Porto Alegre, Brazil
  • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 263422 · Bron, France
  • Thoracic General Hospital of Athens I Sotiria /ID# 261790 · Athens, Greece
  • Ospedale Pediatrico Bambino Gesu /ID# 262379 · Rome, Italy
  • Yonsei University Health System - Severance Hospital /ID# 262721 · Seoul, South Korea
Show 6 removed
  • Hospital Pequeno Príncipe /ID# 262600 · Curitiba, Brazil
  • Santo Antônio Children's Hospital /ID# 262601 · Porto Alegre, Brazil
  • Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 263422 · Bron, France
  • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 261790 · Athens, Greece
  • Ospedale Pediatrico Bambino Gesù /ID# 262379 · Rome, Italy
  • Yonsei University Health System Severance Hospital /ID# 262721 · Seoul, South Korea
Oct 16, 2026
Primary completion
Jun 2027→Jan 2031
Oct 16, 2026
Study completion
Dec 2034→Jan 2031
Oct 16, 2026
Enrollment
110 (estimated)→111 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Active, not recruiting
    6 sites added, 6 sites removed
    Show 6 added (2 Brazil, 1 France, 1 Greece, 1 Italy, 1 South Korea)
    • Hospital Pequeno Principe /ID# 262600 · Curitiba, Brazil
    • Santo Antonio Children's Hospital /ID# 262601 · Porto Alegre, Brazil
    • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 263422 · Bron, France
    • Thoracic General Hospital of Athens I Sotiria /ID# 261790 · Athens, Greece
    • Ospedale Pediatrico Bambino Gesu /ID# 262379 · Rome, Italy
    • Yonsei University Health System - Severance Hospital /ID# 262721 · Seoul, South Korea
    Show 6 removed
    • Hospital Pequeno Príncipe /ID# 262600 · Curitiba, Brazil
    • Santo Antônio Children's Hospital /ID# 262601 · Porto Alegre, Brazil
    • Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 263422 · Bron, France
    • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 261790 · Athens, Greece
    • Ospedale Pediatrico Bambino Gesù /ID# 262379 · Rome, Italy
    • Yonsei University Health System Severance Hospital /ID# 262721 · Seoul, South Korea
    Primary completion Jun 2027→Jan 2031
    Study completion Dec 2034→Jan 2031
    Enrollment 110 (estimated)→111 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06332534
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Aug 8, 2024
Primary completion
Jan 2031 (estimated)
Completion
Jan 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion